Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Allergan’s Oral Drugs Overlooked In CGRP Inhibitor Development Race

Executive Summary

Allergan has two oral CGRP inhibitors – the only small molecules in the drug class in the clinic – but anti-CGRP biologics are likely to hit the market first. However, an effective oral product from a company that’s already marketing a migraine drug – Botox – could be an overlooked contender.


Related Content

Allergan Confident About Continued Growth, Swats Down Competition Concerns
Amgen Plans 2017 Filings After Second Phase III CGRP Inhibitor Success
Allergan’s Namesake Acquisition Looks Well-Timed As Established Brands Falter
3Q Pharma Results Preview: Pfizer, Gilead, Allergan, Valeant, AstraZeneca
Teva Backs Small Molecule CGRP Approach To Migraine With Heptares Deal
Allergan migraine portfolio grows with Merck CGRP antagonists


Related Companies